Adapt Wealth Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)

Adapt Wealth Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 6.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,956 shares of the company’s stock after purchasing an additional 901 shares during the period. Johnson & Johnson comprises 1.5% of Adapt Wealth Advisors LLC’s investment portfolio, making the stock its 21st largest position. Adapt Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Innealta Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $27,000. Christopher J. Hasenberg Inc purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $31,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $43,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $44,000. Finally, Grayhawk Investment Strategies Inc. increased its stake in shares of Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. The Goldman Sachs Group reduced their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 6th. Finally, TD Securities reduced their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Up 0.5 %

Shares of NYSE:JNJ opened at $167.38 on Wednesday. The company has a market cap of $402.92 billion, a P/E ratio of 10.44, a PEG ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The stock’s fifty day moving average price is $158.40 and its 200-day moving average price is $153.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.80 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.